Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma

Authors:

Abstract
No abstract available
Funding Information
  • Novartis

This publication has 22 references indexed in Scilit: